← All trials
NCT06424002
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2024
- Primary completion
- Dec 20, 2024
- Completion date
- Dec 30, 2024
- First posted
- May 21, 2024
- Last posted
- May 21, 2024
- Enrollment
- 5400
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kamuzu University of Health SciencesLead sponsor
- Boston UniversityCollaborator
- Government of MalawiCollaborator
- Kamuzu University of Health SciencesOfficial
- Michigan State UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.